There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report), TScan Therapeutics (TCRX – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments.
Apellis Pharmaceuticals (APLS)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Monday at $43.01.
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals with a $78.17 average price target, representing an 82.2% upside. In a report issued on May 7, Needham also reiterated a Buy rating on the stock with a $85.00 price target.
See today’s best-performing stocks on TipRanks >>
TScan Therapeutics (TCRX)
Barclays analyst Peter Lawson maintained a Buy rating on TScan Therapeutics today and set a price target of $14.00. The company’s shares closed last Monday at $8.01, close to its 52-week high of $9.09.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $12.00, representing a 56.3% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $11.00 price target.
Ascendis Pharma (ASND)
In a report released today, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma, with a price target of $182.00. The company’s shares closed last Monday at $132.02.
According to TipRanks.com, Lebovitz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $188.14 average price target, representing a 40.4% upside. In a report issued on May 2, Goldman Sachs also maintained a Buy rating on the stock with a $170.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLS:
- Apellis price target lowered to $60 from $67 at Citi
- Apellis reports Q1 EPS (54c), consensus (52c)
- Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today
